FDA approved 68Gallium PSMA (68Ga-PSMA) in 2020, and [18F]DCFPyL, a Fluorine-18 labeled PSMA ligand, popularly known as Pylarify in 2021 as the first and second PSMA-based PET tracer for management of patients with prostate cancer who had a biochemical recurrence. This evidence concerns the gene FOLH1 and Familial prostate cancer.